Comparison of the effectiveness, safety and tolerability of Perampanel and Levetiracetam as monotherapy in Chinese patients with focal-onset seizures: A single-center, ambispective, open-label, real-world observational study. [PDF]
Ma H +9 more
europepmc +1 more source
Comment on "Incidental interictal epileptiform discharges in infants with nonepileptic events" by Montenegro et al. [PDF]
Seeck M +6 more
europepmc +1 more source
Resolution of generalized tonic seizures following focal ablative or resective surgery. [PDF]
Kampman SL +3 more
europepmc +1 more source
Objective outcome assessment in epilepsy surgery using ultralong-term subcutaneous EEG: A case report. [PDF]
Lisy T +7 more
europepmc +1 more source
A two-sample Mendelian randomization study and mediation analysis exploring the link between cathepsins and epilepsy. [PDF]
Sun H +7 more
europepmc +1 more source
Trajectories of quality of life, anxiety and depressive symptomatology, and health-related work productivity after first seizure events. [PDF]
Foster E +13 more
europepmc +1 more source
A multi-feature method for real-time seizure detection in pediatric intensive care unit. [PDF]
Sang T +10 more
europepmc +1 more source
Related searches:
Focal Status Epilepticus and Epilepsia Partialis Continua in Adults and Children
Epilepsia, 1993Summary: Focal status epilepticus and epilepsia partialis continua (FSE‐EPC) are most frequently seen with chronic focal progressive encephalitis of Rasmussen and Russian spring‐summer encephalitis. FSE‐EPC may be the presenting feature of nonketotic hyperglycemic diabetes mellitus but is more often noted as a late complication especially if there is ...
exaly +3 more sources
Oxcarbazepina en el tratamiento de la epilepsia focal refractaria.
Gaceta Medica De Bilbao, 2007Resumen Introduccion Los objetivos del estudio son analizar la eficacia y la tolerabilidad de la oxcarbazepina en pacientes afectos de epilepsia focal refractaria. Material y metodos Estudio prospectivo con treinta pacientes tratados con oxcarbazepina a dosis de 1.200–1.800 mg. Visita basal y visitas a los dos, cuatro y seis meses. Resultados
José Mª. Losada +5 more
exaly +2 more sources

